S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Will Plug Power’s Deal With Energy Vault Move The Needle? 
OTCMKTS:NWBO

Northwest Biotherapeutics (NWBO) Stock Forecast, Price & News

$0.73
0.00 (0.00%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.72
▼
$0.79
50-Day Range
$0.49
▼
$0.73
52-Week Range
$0.45
▼
$1.27
Volume
2.27 million shs
Average Volume
1.35 million shs
Market Capitalization
$795.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest

NWBO stock logo

About Northwest Biotherapeutics (OTCMKTS:NWBO) Stock

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

Receive NWBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

NWBO Stock News Headlines

May 27, 2023 | finance.yahoo.com
NWBO - Northwest Biotherapeutics, Inc.
May 9, 2023 | thestreet.com
Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study
June 10, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 9, 2023 | americanbankingnews.com
Financial Survey: Genprex (NASDAQ:GNPX) & Northwest Biotherapeutics (OTCMKTS:NWBO)
May 5, 2023 | americanbankingnews.com
Reviewing Northwest Biotherapeutics (NWBO) and Its Peers
April 22, 2023 | americanbankingnews.com
Northwest Biotherapeutics (NWBO) and Its Rivals Financial Review
April 19, 2023 | americanbankingnews.com
Head to Head Review: Northwest Biotherapeutics (NWBO) vs. Its Peers
April 19, 2023 | americanbankingnews.com
Head to Head Review: Northwest Biotherapeutics (NWBO) vs. Its Peers
June 10, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
April 13, 2023 | health.usnews.com
Northwest Medical Center-Tucson
March 21, 2023 | finance.yahoo.com
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
March 11, 2023 | finance.yahoo.com
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
March 9, 2023 | msn.com
Northwest Bio in $11M loan agreement with Streeterville Capital
January 6, 2023 | bizjournals.com
Brown-Lifespan researchers advance new vaccine to treat brain cancer
January 6, 2023 | finance.yahoo.com
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
December 1, 2022 | ft.com
US cancer drug company accuses market makers of stock spoofing
December 1, 2022 | benzinga.com
Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation
December 1, 2022 | finance.yahoo.com
Cancer drug company accuses US market makers of stock spoofing
November 23, 2022 | seekingalpha.com
Northwest Biotherapeutics: Data Is Done, Just Wait For Approval
November 18, 2022 | finance.yahoo.com
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
October 18, 2022 | seekingalpha.com
Northwest Biotherapeutics: Biopharma's Promising Delinquent
October 10, 2022 | usnews.com
US Officials Seek Public Comment on Pacific Northwest Trail
September 15, 2022 | seekingalpha.com
NWBO Northwest Biotherapeutics, Inc.
August 23, 2022 | finance.yahoo.com
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
August 10, 2022 | apnews.com
Northwest Biotherapeutics: Q2 Earnings Snapshot
July 6, 2022 | finance.yahoo.com
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
May 10, 2022 | seekingalpha.com
Northwest Bio plunges after late-stage data for lead candidate in brain cancer
See More Headlines

NWBO Price History

NWBO Company Calendar

Last Earnings
8/10/2015
Today
6/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:NWBO
Previous Symbol
NASDAQ:NWBO
CUSIP
N/A
CIK
1072379
Web
www.nwbio.com
Phone
(240) 497-9024
Fax
240-627-4121
Employees
19
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-105,030,000.00
Net Margins
-4,697.69%
Pretax Margin
-4,697.69%
Return on Equity
-50.86%
Return on Assets
-330.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$1.68 million
Price / Sales
473.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-6.08

Miscellaneous

Outstanding Shares
1,090,030,000
Free Float
987,565,000
Market Cap
$795.18 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Linda F. Powers
    Chairman, President, CEO & Chief Financial Officer
  • Alton L. Boynton
    Secretary, Director & Chief Scientific Officer
  • Marnix L. Bosch
    Chief Technical Officer
  • Leslie J. Goldman
    Head-Business Development, SVP & General Counsel
  • David Innes
    Vice President-Investor Relations

Key Competitors

View All Competitors













NWBO Stock - Frequently Asked Questions

How have NWBO shares performed in 2023?

Northwest Biotherapeutics' stock was trading at $0.7845 at the start of the year. Since then, NWBO shares have decreased by 7.0% and is now trading at $0.7295.
View the best growth stocks for 2023 here.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) posted its earnings results on Monday, August, 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.22. The biotechnology company earned $0.39 million during the quarter, compared to analysts' expectations of $0.20 million. Northwest Biotherapeutics had a negative net margin of 4,697.69% and a negative trailing twelve-month return on equity of 50.86%.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP).

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.73.

How much money does Northwest Biotherapeutics make?

Northwest Biotherapeutics (OTCMKTS:NWBO) has a market capitalization of $795.18 million and generates $1.68 million in revenue each year. The biotechnology company earns $-105,030,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The official website for the company is www.nwbio.com. The biotechnology company can be reached via phone at (240) 497-9024, via email at lgoldman@nwbio.com, or via fax at 240-627-4121.

This page (OTCMKTS:NWBO) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -